Tempest Therapeutics TPST stock skyrocketed 2879% after it announced positive new data from its global phase Ib/II first-line liver cancer study, evaluating TPST-1120, in combination with the standard ...

Tempest Therapeutics, Inc. TPST announced that it is planning to explore strategic options to advance the clinical studies on its pipeline candidates aimed at increasing stockholder value. The ...

Tempest Therapeutics (NASDAQ:TPST) said its drug TPST-1120 showed clinically-meaningful improvement in multiple categories in patients with a type of liver cancer as per early data from a phase 1b/2 ...

Today, most of Wall Street is watching Tempest Therapeutics (NASDAQ:TPST). This little-known clinical-stage oncology company has gone from trading at 30 cents per share 24 hours ago to its current ...

The average one-year price target for Tempest Therapeutics (NASDAQ:TPST) has been revised to 22.10 / share. This is an increase of 38.30% from the prior estimate of 15.98 dated October 4, 2023. The ...

What To Know: While the deal expands Tempest’s pipeline, the market is reacting negatively to significant shareholder dilution. Tempest will issue roughly 8.27 million new shares to Factor, equivalent ...

Tempest Therapeutics (NASDAQ: TPST) stock is up 3,800% on the full day. TPST stock has reacted to the company’s announcement that it’s drug for a certain type of liver cancer seems to actually work.

10 Stocks to Sell NOW! 3 Stocks to DOUBLE This Year The 10 Best Stocks to Own in 2023 7 Stocks to Buy and Hold Forever Tempest Therapeutics, Inc, a clinical-stage oncology company, develops small ...